Oct. 2. Johnson & Johnson (J&J) will create 420 jobs in Wilson County with a $2 billion investment in a new pharmaceutical manufacturing campus for innovative biologics in the City of Wilson.
With expertise in Innovative Medicine and MedTech, Johnson & Johnson is uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Quotable
“A strong, global supply chain is crucial, and we purposefully invest to ensure our transformational medicines reliably and efficiently reach patients around the world,” said Dapo Ajayi, a vice president at J&J. “North Carolina is an important hub for biopharmaceutical manufacturing and talent, and we are pleased to join this thriving life sciences ecosystem and become part of the Wilson community.”
Pay
New positions for the project will include analysts, engineers, microbiologists, scientists, specialists, managers and senior leaders. Although salaries will vary by position, the average annual wage is $108,823, which exceeds the Wilson County average of $52,619. The new jobs could create a potential payroll impact of more than $45.7 million for the region each year.
Details
J&J’s project in North Carolina will be facilitated, in part, by a Job Development Investment Grant (JDIG) awarded to Janssen Biotech, Inc. (a subsidiary of J&J), which was approved by the state’s Economic Investment Committee earlier today. Over the course of the 12-year term of this grant, the project is estimated to grow the state’s economy by $2.3 billion.
Using a formula that takes into account $1 billion of the company’s investment as well as the new tax revenues generated by the new jobs, the JDIG agreement authorizes the potential reimbursement to the company of up to $13,666,000, spread over 12 years. State payments only occur following performance verification by the departments of Commerce and Revenue that the company has met its incremental job creation and investment targets.
Discussion
No comments yet.